Researches On The Change Of Survivin Autoantibody In Four Types Of Malignancies

Malignancies are the major health problems in the world.Their incidence and mortality have shown a clearly upward trend,which has caused huge health and economic burdens.The current detection techniques still have many shortcomings.Therefore,it is still necessary to find clinically more reliable diagnostic methods to achieve early detection and early treatment.Recently,methods for early diagnosis of malignancy associated antigens have been recognized gradually,with a significant increase in sensitivity compared to the detection of antigens.In this study,Survivin autoantibody in the sera of four types of malignancies was detected by a modified ELISA,and its value as an early diagnostic marker of malignant tumors was explored.Method:In this study,Survivin autoantibody in serum of 267 cases of lung cancer,159 cases of esophageal cancer,144 cases of liver cancer,124 cases of breast cancer and 362 healthy people were detected by modified ELISA method.The expression of autoantibody in tumors and healthy controls was evaluated by using specific binding index(SBI).The reliability and stability of the results were evaluated by calculating the discrete degree of the repeat holes and the degree of variation of quality control blood.SPSS 22.0 was used for statistical analysis.The expression of Survivin autoantibody in different tumors and stages was compared to explore the role of Survivin in tumor diagnosis.Result:⑴The expression of Survivin autoantibody in lung cancer patients was significantly higher than that in healthy controls(P=0.000).The area under ROC curve was 0.713,and the sensitivitiy to 90.0% specificity was 17.2%.Survivin autoantibody was significantly higher in early and late patients than in healthy controls(P=0.000;P=0.000),slightly higher in early stage but no significant difference(P=0.248).The sensitivities were 18.7% and 16.7%,respectively.In thedetection of lung cancer,the predictive values of both the positive and negative were good,with certain diagnostic value.⑵The expression of Survivin autoantibody in esophageal cancer patients was slightly lower than that in the control group(P=0.524).The area under the ROC curve was 0.327,and the sensitivity to90.0% specificity was 14.5%.Survivin autoantibody showed no significant difference in early and late patients compared with healthy controls(P=0.495;P=0.754).The sensitivities to 90% specificity were 16.9% and 12.2%,respectively.The predictive values of both the positive and negative were good for Survivin autoantibody in the detection of esophageal cancer,but the sensitivity was low.The diagnostic value was not high.⑶The level of Survivin autoantibody in liver cancer patients was significantly lower than that in the control group(P=0.001).The area under the ROC curve was 0.306,and the sensitivity to 90.0% specificity was 10.5%.The level of autoantibody to Survivin in early patients was significantly lower than that of healthy controls(P=0.000)while the level of autoantibody in late patients was slightly lower than healthy controls(P=0.179),and the sensitivities to 90% specificity were 10.3%and 10.7%,respectively.Although Survivin autoantibody had an obvious staging differences(P=0.000)in the detection of liver cancer patients,the efficiency of detection was poor,which still need a further improvement.⑷The expression of Survivin autoantibody in breast cancer patients was higher than that in the female control group(P=0.033).The area under the ROC curve was 0.590 and the sensitivity to 90.0% specificity was 21.8%.Early patients had a significantly higher level of autoantibody against Survivin than female healthy controls(P=0.024).The level of autoantibody in late patients were slightly higher than healthy controls(P=0.549).The detection efficiency of Survivin autoantibody in breast cancer was high and the sensitivity was good,with a certain diagnostic value.Conclusion: ⑴The expressions of Survivin autoantibody in lung cancer and breast cancer patients were significantly increased,and the sensitivity and specificity were good,which was of great value for the diagnosis but still needed to be optimized.⑵The level of Survivin autoantibody in patients with liver cancer was significantly reduced,but the efficiency of detection needed to be improved.We still needed tofurther expand the sample size.⑶The level of Survivin autoantibody in esophageal cancer had no value for its diagnosis.⑷The application of modified ELISA detection of Survivin autoantibody on the tumor diagnosis had a certain diagnostic value and broad prospectsas as a new method.